

Info Sheet for Technical description

No. 0005

Organization

\* Mandatoty fields

|                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                        |  |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--|
| Name of Organization*                                      | Innovacell Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                        |  |
| Address, City, States, Zip, Country*                       | MEGURO VILLA GARDEN 5F, 3-5-11 KAMIOSAKI SHINAGAWA-KU, TOKYO, 141-0021 Japan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                        |  |
| URL                                                        | <a href="https://www.innovacell.co.jp/">https://www.innovacell.co.jp/</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                        |  |
| Brief Descriptions of Organization*<br>(Approx. 100 words) | Innovacell was founded in 2000 as a spin-off from the Medical University of Innsbruck in Austria. In 2021, the company relocated its headquarters to Tokyo, Japan, and now operates as a group with Innovacell K.K. in Japan and Innovacell GmbH in Austria. Its pipeline includes two late-stage clinical programs, ICEF15 and ICES13, and one pre-clinical program, ICEF16, all targeting various forms of incontinence. ICEF15, an autologous skeletal myoblast cell therapy, is in a multi-regional Phase III trial across Europe and Japan. In 2025, Innovacell successfully raised JPY 7.3 billion in Series D financing from global investors. |                                                                                        |  |
| Contact address                                            | Name*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Colin Lee Novick                                                                       |  |
|                                                            | Department* / Position                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Co-CEO                                                                                 |  |
|                                                            | E-mail* / TEL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | colin@innovacell.co.jp/080-4422-0403<br>Assistant email : eimi.tamura@innovacell.co.jp |  |

What kind of technology do you want to offer? \*

- ☒ **A.** Clinical Development Pipelines
- Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(\*) that are not included in the above (Group B)
- Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☒ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☒ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

|                                         |          |
|-----------------------------------------|----------|
| Options*                                | Comments |
| <input checked="" type="checkbox"/> Yes |          |
| <input type="checkbox"/> No             |          |

Filled in by\*

Date\*

|                  |
|------------------|
| Colin Lee Novick |
| 2025/8/28        |

**Sheet [A]** Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0005-1

\* Mandatoty fields

**Title\***ICEF15**Development Phase\***

- |                                                   |                                                    |                                                                |
|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|
| <input type="checkbox"/> Basic Research           | <input type="checkbox"/> Drug Discovery            | <input type="checkbox"/> Pre-Clinical                          |
| <input type="checkbox"/> Clinical Trial (Phase I) | <input type="checkbox"/> Clinical Trial (Phase II) | <input checked="" type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review                   | <input type="checkbox"/> Others                    |                                                                |

**Diesease Area\***

- |                                          |                                                     |                                         |
|------------------------------------------|-----------------------------------------------------|-----------------------------------------|
| <input type="checkbox"/> Cancer          | <input type="checkbox"/> Central nervous system     | <input type="checkbox"/> Ophthalmology  |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism     | <input type="checkbox"/> Cardiovascular |
| <input type="checkbox"/> Urogenital      | <input checked="" type="checkbox"/> Digestive organ | <input type="checkbox"/> Blood          |
| <input type="checkbox"/> Infection       | <input type="checkbox"/> Dermatology                | <input type="checkbox"/> Immunity       |
| <input type="checkbox"/> Otolaryngology  | <input type="checkbox"/> Respiratory                | <input type="checkbox"/> Others         |

**Description\***

Autologous cell therapy for the treatment fecal (urge) incontinence

Multi-Regional Phase III Clinical Trial (Ongoing):

- ClinicalTrials.gov ID: NCT04976153
- EudraCT Number: 2021-001376-42

Phase IIb Study:

- EudraCT Number: 2010-021463-32

Publications:

- <https://pubmed.ncbi.nlm.nih.gov/19875391/>
- <https://pubmed.ncbi.nlm.nih.gov/25773013/>
- <https://pubmed.ncbi.nlm.nih.gov/30213273/>
- <https://pubmed.ncbi.nlm.nih.gov/35961517/>
- <https://pubmed.ncbi.nlm.nih.gov/29566057/>
- <https://www.nature.com/articles/nrgastro.2010.13>

**Filled in by\***

Colin Lee Novick

**Date\***

2025/8/28